| Similar Articles |
|---|
 |
Bio-IT World
January 12, 2004
Kevin Davies |
The Ultimate Platform Firm Greg Lucier on determinism in drug development at Invitrogen   |
Bio-IT World
October 2005 |
News Blast One Stop... New Strand... Emerging... Appointment... |
The Motley Fool
October 12, 2005
Carl Wherrett |
Q-Dots No More Quantum Dot sells out to Invitrogen. Will the absence of an IPO window will push other private nanotech companies to sell now rather than go through the arduous process of a public listing? |
Bio-IT World
March 2006
Robert M. Frederickson |
Integration, Robotics, and Automation The integration of instruments and technology is a key concept driving the development of advanced life-sciences laboratory automation. More sophisticated robotics are also increasingly being integrated into automated systems. |
The Motley Fool
December 30, 2003
Tom Taulli |
M&A As Strong Medicine Invitrogen's latest deal shows that the company knows where its market is headed. |
Bio-IT World
September 11, 2003
Malorye Branca |
The Odd Couple CombinatoRx brings matchmaking to drug discovery and development. |
The Motley Fool
May 17, 2006
Stephen D. Simpson |
Angiotech Pharmaceuticals: Rebuilding or Reloading? This small Canadian drug-delivery outfit is reshaping and diversifying. Investors, is it time to buy? |
